| 產(chǎn)品名稱 | GSK 1838705A - GSK 1838705 |
| 產(chǎn)品貨號 | Axon 2267 CAS [1116235-97-2] MF C27H29FN8O3MW 532.57 Purity: 99% Soluble in DMSO Description Potent and selective insulin-like growth factor-1 receptor (IGF-IR) and insulin receptor (IR) kinase inhibitor with additional affinity for anaplastic lymphoma kinase (ALK) with IC50 values of 2.0 nM, 1.6 nM, and 0.6 nM, for IGF1R, IR, and ALK respectively, and >800-fold selectivity over related kinases, including RSK1, JNK3, and B-Raf V600EGSK 1838705A inhibits the proliferation of cancer cell lines, comprises the growth of human tumor xenografts in vivo, and causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses. References Certificates Categories Extra info S.D. Chamberlain et al. Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity. Bioorg. Med. Chem. Lett. 2009, 19, 360-364. ? P. Sabbatini et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol. Cancer Ther. 2009, 8, 2811-20. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology ALK IGF1R Endocrinology RTK class II; EC 2.7.10.1 IR Potent IGF-IR and insulin receptor (IR) kinase inhibitor with additional affinity for ALK Chemical name 2-(2-(1-(2-(dimethylamino)acetyl)-5-methoxyindolin-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-6-fluoro-N-methylbenzamide Parent CAS No. [1116235-97-2] Order Size Unit Price Stock 5 mg €110.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
GSK 1838705A - GSK 1838705Axon 2267 CAS [1116235-97-2] MF C27H29FN8O3
Description
Potent and selective insulin-like growth factor-1 receptor (IGF-IR) and insulin receptor (IR) kinase inhibitor with additional affinity for anaplastic lymphoma kinase (ALK) with IC50 values of 2.0 nM, 1.6 nM, and 0.6 nM, for IGF1R, IR, and ALK respectively, and >800-fold selectivity over related kinases, including RSK1, JNK3, and B-Raf V600EGSK 1838705A inhibits the proliferation of cancer cell lines, comprises the growth of human tumor xenografts in vivo, and causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses.
Potent IGF-IR and insulin receptor (IR) kinase inhibitor with additional affinity for ALK
Chemical name2-(2-(1-(2-(dimethylamino)acetyl)-5-methoxyindolin-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-6-fluoro-N-methylbenzamide Parent CAS No.[1116235-97-2] |
| 產(chǎn)品資料 |
